BOOG organisation in English

 


Dutch Breast Cancer Research Group (Borstkanker Onderzoek Groep; BOOG)

The Borstkanker Onderzoek Groep (BOOG) or in English, the Dutch Breast Cancer Research Group, is a collaborative study group that was founded in April 2001 with the aim of initiating, promoting, coordinating and facilitating clinical breast cancer trials. In particular, the group's focus lies on the development and conduct of phase II and III trials.
    
BOOG performs national as well as international (BIG, EORTC, GBG, IBCSG) breast cancer trials relevant for the current state of the Dutch healthcare system on a broad basis in the Netherlands. An official membership is not required, but any physician who takes part in BOOG's trials automatically joins the study group. BOOG has acquired a good reputation among many Dutch scientific researchers. Each hospital in the Netherlands is participating in at least one BOOG study, and nearly 100 clinical institutions and 350 investigators are working to facilitate the entry of their patients into an appropriate BOOG trial. In 2009 about 2,500 patients were enrolled: this is an impressive number, considering that the annual incidence of newly diagnosed breast cancer patients in The Netherlands is 13,000.
    
BOOG also collaborates with 11 pharmaceutical companies that are interested in the conduct of clinical breast cancer trials in the Netherlands. To avoid conflict of interest of standard clinical care, the BOOG Foundation has been established.  In February 2008, BOOG started its own company, the BOOG Study Center B.V. This Study Center represents the operative and legal platform for the conduct of BOOG's trials.
The BOOG Board consists of seven members. The BOOG Study Center employs four individuals. Six individuals employed by the Comprehensive Cancer Center Amsterdam also work in part for BOOG.
    
In April 2008 four indication specific working parties were established: (neo)adjuvant, loco-regional, advanced and metastatic disease, and translational research. These working parties monitor the studies' portfolio and initiate new studies in their specific indication. The members of these working parties are opinion leaders in the field of breast cancer treatment and research in the Netherlands; they are selected by the BOOG Board, which ensures that different disciplines and geographical areas are represented. If a decision is made about a new study project within a sub-board, the BOOG Study Center takes over the planning, organisation and conduct of the trial.
    
A patient advisory group gives feedback on BOOG trials from their patient perspective. They give advice on practical aspects and relevance of the trial and they review study information for patients. A nursing advisory group is also active and gives practical and logistical advice about the implementation of BOOG trials in clinical settings. This group also participates in the development of nursing protocols.

Furthermore, once a year BOOG organizes a symposium that summarizes the main results of the San Antonio Breast Cancer Symposium, and those of either the St. Gallen conference or the European Breast Cancer Conference. During the BOOG symposium, prominent Dutch investigators report the latest findings in breast cancer clinical treatment and research. Their relevance is then discussed in the context of the trials running in the Netherlands and in the context of the Dutch guidelines for treatment.

For an overview of all BOOG trials, click here.